MTOR and intrahepatic cholangiocarcinoma: Overexpression of EGFR, VEGF, VEGFR and mTOR proteins as determined by ICC were seen in up to 805 (62%) cases indicating the possibility of selection of respective targeted therapies against EGFR, angiogenesis and mTOR pathways.